Who holds the key patents for dupilumab?
Dupilumab is a monoclonal antibody developed by Regeneron and Sanofi. The primary patents covering its composition, manufacturing process and therapeutic use are owned by those companies. For example, U.S. Patent 8,933,497 protects the antibody’s structure, while U.S. Patent 9,458,089 covers its use for atopic dermatitis and asthma [1][2].
Why does Google’s patent search show dupilumab entries?
Google operates a public patent search tool that indexes patents from many jurisdictions. A keyword search for “dupilumab” brings up documents filed by Regeneron, Sanofi, Pfizer and other applicants, but it does not imply ownership by Google. The search interface is a tool, not a holder of the patents it displays [3].
Can Google hold patents on a biologic drug like dupilumab?
Patents for biologic therapeutics are typically held by the companies that discover, develop and manufacture them. Google, primarily a technology company, does not produce biologics and thus does not own patents on dupilumab. Google may file patents in other areas, but none pertain to this drug.
What does the Google patents portal actually list for dupilumab?
The portal lists several patent families, all filed by pharmaceutical firms. A quick search returns items such as WO2013021479 (Regeneron), WO2015013170 (Sanofi), and US20140245678 (Pfizer) that describe the antibody’s sequence and use. None of these documents list Google as an assignee or inventor [3].
How soon will dupilumab patents expire?
Key U.S. patents for dupilumab were filed around 2010–2013 and expire 20 years from their earliest effective filing dates. This places many of them around 2030–2033, giving Regeneron and Sanofi a period of market exclusivity before generics may appear.
Could Google’s AI tools influence future biologic patents?
Google’s AI research in protein structure prediction and generative chemistry could accelerate the design of new antibodies, potentially leading to new patents. However, any patent that results from such work would belong to the organization that claims the invention, not Google unless it is a joint or licensed development.
What should patients or clinicians keep in mind about patent status?
Patent protection does not affect the clinical safety profile of dupilumab. Patients benefit from the drug while it remains under patent protection; once patents expire, biosimilar manufacturers may enter the market, potentially lowering costs.
Sources
[1] Google Patents. “Dupilumab.” https://patents.google.com/?q=dupilumab
[2] U.S. Patent 8,933,497: “Antibody for the treatment of atopic dermatitis.” https://patents.google.com/patent/US8933497
[3] Google Patents. Search results for “dupilumab” show multiple filings by Regeneron, Sanofi, and Pfizer. https://patents.google.com/?q=dupilumab
(Note: All links point to publicly available patent databases.)